Sarepta Therapeutics Stock in Focus

Shares of Sarepta Therapeutics have moved -0.1% today, and are now trading at a price of $88.06. In contrast, the S&P 500 index saw a -0.0% change. Today's trading volume is 172,490 compared to the stock's average volume of 1,539,511.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. Based in Cambridge, United States the company has 1,162 full time employees and a market cap of $8,237,722,624.

The company is now trading -37.23% away from its average analyst target price of $140.28 per share. The 18 analysts following the stock have set target prices ranging from $80.0 to $224.0, and on average give Sarepta Therapeutics a rating of buy.

Over the last 12 months SRPT shares have declined by -26.0%, which represents a difference of -43.0% when compared to the S&P 500. The stock's 52 week high is $159.89 per share and its 52 week low is $55.25. Based on Sarepta Therapeutics's average net margin growth of 10.3% over the last 3 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023 1,104,982 -690,876 -63 16.0
2022 933,013 -703,488 -75 -25.0
2021 701,887 -418,780 -60 41.75
2020 540,099 -554,128 -103 45.21
2019 380,833 -715,075 -188 -56.67
2018 301,034 -361,918 -120
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.